Table 2 Symptomatology at presentation
From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
| Â | Total no. = 33 |
|---|---|
Fever | 14 (42.4%) |
Facial numbness | 20 (60.6%) |
Facial swelling | 19 (57.6%) |
Headache | 23 (69.7%) |
Facial pain | 23 (69.7%) |
Rhinorrhea, blood stained | 11 (33.3%) |
Orbital swelling | 23 (69.7%) |
Ophthalmoplegia | 18 (54.5%) |
Visual loss | 16 (48.5%) |
Disturbed conscious | 8 (24.2%) |
Motor or sensory weakness (stroke) | 6 (18.2%) |
First presentation | |
 Eye swelling | 5 (55.6%) |
 Disturbed conscious | 3 (33.3%) |
 Facial swelling | 1 (11.1%) |
Intranasal necrosis | 29 (87.9%) |
Palatal necrosis | 19 (57.6%) |
Ophthalmoplegia | 18 (54.5%) |
Proptosis | 13 (39.4%) |
Visual loss | 16 (48.5%) |
Cavernous sinus thrombosis | 18 (54.5%) |
Facial skin necrosis | 2 (6.1%) |
Cranial nerves involvement | |
 Negative | 27 (81.8%) |
 Facial | 6 (18.2%) |